Relevance of Bone Scintigraphy in the Diagnostic Algorithm for Examining Treatment-Naive Pediatric Patients with Langerhans Cell Histiocytosis: a Retrospective Cohort Study
Open Access
- 24 July 2019
- journal article
- Published by Paediatrician Publishers LLC in Oncopediatrics
- Vol. 6 (2), 94-105
- https://doi.org/10.15690/onco.v6i2.2021
Abstract
Background. Histiocytosis is a heterogeneous group of rare diseases of unknown etiology. Langerhans cell histiocytosis (LCH) is characterized by an abnormal proliferation of histiocytes (activated dendric cells and macrophages). LCH is the most common form of histiocytosis, it is a potentially fatal diseases. Early detection of LCH plays an important role in its prognosis and outcome. However, the role of advanced methods of nuclear medicine in diagnosis of LCH is still to be researched. We have long-term experience in observing pediatric patients with LCH. Taking into the account the difficulty of diagnostic task for bone scintigraphy in identifying lytic bone destruction, we stated the following objective of the study. Objective. Our aim was to perform retrospective analysis of bone scintigraphy examinations of treatment-naive pediatric patients with LCH and calculate the diagnostic efficacy of bone scintigraphy. Methods. We retrospectively analyzed 55 examinations of treatment-naive pediatric patients (the median age was 5.9 years) with proven case of LCH (2014–2018). Results. During examination we visualized 82 lesions with pathological level of accumulation of radiopharmaceutical in 55 patients. 78 with high level of accumulation (>120%); 3 with slightly increased level of accumulation (100–120%) and 1 with lower than normal level of accumulation (Keywords
This publication has 15 references indexed in Scilit:
- Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell HistiocytosisThe American Journal of Surgical Pathology, 2018
- Adult-onset Langerhans cell histiocytosis of the sternumJournal of Thoracic Disease, 2017
- PET/MR in the Assessment of Pediatric HistiocytosesClinical Nuclear Medicine, 2017
- Denosumab for the treatment of adult multisystem Langerhans cell histiocytosisMetabolism, 2017
- 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensificationBlood, 2008
- Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorMedical and Pediatric Oncology, 2002
- A randomized trial of treatment for multisystem Langerhans’ cell histiocytosisThe Journal of Pediatrics, 2001